Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease Mar 04, 2024
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy Feb 22, 2024
Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market Jan 29, 2024
Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference Jan 11, 2024
Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds Jan 05, 2024
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea Jan 05, 2024
Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol Jan 04, 2024
Fortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Jan 03, 2024
